【摘要】 目的:探讨乳腺癌组织中转化生长因子β1(transforming growth factorβ1,TGF-β1)与微血管密度(microvessel density,MVD)及乳腺癌预后的相关性。方法:采用免疫组织化学方法检测62例乳腺癌组织及30例乳腺腺瘤组织中TGF-β1的表达水平,计数MVD,分析二者与乳腺癌病理特征的关系。结合随访资料分析TGF-β1与乳腺癌的复发转移及患者生存率的相关性。结果:乳腺癌组织中TGF-β1蛋白表达的阳性率、MVD计数均明显高于乳腺腺瘤组织(P<0.05);乳腺癌组织中TGF-β1蛋白表达的阳性率随肿瘤直径的增加、临床分期增高及淋巴结转移而增高(P<0.05),且MVD计数与临床分期及淋巴结转移相关(P<0.05)。TGF-β1蛋白表达水平与乳腺癌组织MVD计数呈正相关(r=0.705,P<0.05)。术后5年,TGF-β1蛋白阳性表达患者的生存率明显低于阴性表达患者(P<0.05)。结论:TGF-β1在乳腺癌组织中呈过表达状态且与MVD计数呈正相关,在乳腺癌发生、发展过程中发挥重要作用,有望成为乳腺癌抗血管形成治疗的生物靶点。更多还原

【Abstract】 Objective:To explore the correlation of the expression of transforming growth factorβ1(TGF-β1)in breast cancer tissues with the microvessel density(MVD)in breast cancer tissues,as well as the prognosis of breast cancer patients.Methods:The expression of TGF-β1in the tissues of breast cancer(n=62)and breast fibroadenoma(n=30)were detected with immunohistochemical staining,and the MVD was counted.The correlation of the two factors with the pathological features were analyzed.The influence of TGF-β1 on recurrence,metastasis and survival rate were analyzed in combination with the follow-up data.Results:The positive expression rate of TGF-β1 protein and the count of MVD in breast cancer tissues were significantly higher than those in breast fibroadenoma tissues(P<0.05).The positive expression rate of TGF-β1 protein in breast cancer tissues increased as the increase of tumor diameter,clinical stage,lymph node metastasis(P<0.05),and the count of MVD was correlated with clinical stage and lymph node metastasis(P<0.05).The expression level of TGF-β1 protein was positively correlated with the count of MVD in breast cancer tissues(r=0.705,P<0.05).The 5-year survival rate in patients with positive expression of TGF-β1 was significantly lower than those with negative expression of TGF-β1(P <0.05).Conclusions:TGF-β1 is overexpressed in breast cancer tissues and is positively correlated with the count of MVD.TGF-β1plays an important role during the process of occurrence and development in breast cancer,and it is a potential biological target for anti-angiogenesis therapy in breast cancer.更多还原